MedTrace Logo

Glutamine Supplement in MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes) Syndrome

NCT04948138 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2022-02-24

No results posted yet for this study

Summary

The purpose of this study is to assesses the efficacy of oral supplementation with glutamine over three months on several amino acids and lactate concentration measured in cerebrospinal fluid and cerebral lactate measured by magnetic resonance spectroscopy.

Conditions

  • MELAS Syndrome

Interventions

DIETARY_SUPPLEMENT

Glutamine oral supplementation

Oral supplementation with 10-15 g/day of glutamine (adjusted for weight and plasma concentrations).

Sponsors & Collaborators

  • Jesús González de la Aleja Tejera

    lead OTHER

Principal Investigators

  • Jesús González de la Aleja Tejera, MD, PhD · Hospital Universitario 12 de Octubre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-28
Primary Completion
2021-09-09
Completion
2021-10-06

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04948138 on ClinicalTrials.gov